GeneDx Holdings Corp. (WGS)

GeneDx Holdings Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Net Income	-175.77	-548.98	-245.39	-241.34	-32.74
Depreciation & Amortization	33.73	59.31	23.36	14.13	6.23
Share-Based Compensation	-0.33	41.98	219.42	120.23	5.48
Other Operating Activities	-37.79	128.54	-187.83	13.85	-0.74
Operating Cash Flow	-180.15	-319.16	-190.43	-93.13	-18.73
Capital Expenditures	-1.68	-14.32	-20.79	-31.97	-15.46
Acquisitions	-12.14	-127	0	0	0
Change in Investments	-29.91	0	0	0	0
Investing Cash Flow	-43.73	-141.33	-20.79	-31.97	-15.46
Share Issuance / Repurchase	143.29	200.61	563.29	0	30.9
Debt Issued / Paid	42.95	-3.29	-14.01	11.73	-1.71
Other Financing Activities	-	-	-55.56	117.32	118.82
Financing Cash Flow	186.24	197.32	493.73	129.06	148.01
Net Cash Flow	-37.64	-263.17	282.51	3.95	113.83
Free Cash Flow	-181.82	-333.48	-211.22	-125.1	-34.18
Free Cash Flow Margin	-89.76%	-142.09%	-99.54%	-69.76%	-17.43%
Free Cash Flow Per Share	-7.48	-32.58	-64.49	-804592.08	-9096327.83

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).